Sexual health is an important part of a person’s physical and mental health. Sexual health leads to the healthy sexual life without any sexual dysfunctions, and preventive measures to avoid sexually transmitted infections. The adult population largely suffers from one or more sexual disorders such as dyspareunia, erectile dysfunctions, hypoactive sexual desire disorder, premature (early) ejaculation, and others. According to National Center for Biotechnology Information 2016, sexual dysfunction is highly prevalent, and affects around 43% of women and 31% of men, globally. Currently, various treatment options such as medication, mechanical aids, sexual therapies, and others are available for treating such sexual dysfunctions and to improve sexual health of the person.
Market Dynamics
Increasing incidence and prevalence of sexual disorders is a major factor augmenting growth of the market. Some of the major factors which cause sexual dysfunction are aging population, stressful and unhealthy lifestyle, and other psychological parameters. According to a study published in the National Center for Biotechnology Information in April 2016, hypoactive sexual desire disorder (HSDD) is present in around 8.9% and 12.3% women in the age group of 18 - 44 years and 45 – 64 years, respectively.
Moreover, robust product development activities by major key players is engaged in the introduction of innovative and highly effective drug treatment for improving sexual health. For instance, in June 2019, AMAG Pharmaceuticals received the U.S. FDA approval for Vyleesi (bremelanotide) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Thus, increasing approvals by regulatory authorities are expected to drive the growth of the sexual health market.
Key features of the study:
- This report provides in-depth analysis of the global sexual health market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2020-2027), considering 2018 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles leading players in the global sexual health market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, government initiatives, technological upgradation, market expansion, and marketing tactics
- The global sexual health market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the sexual health market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Sexual Health Market, By Product Type:
- Erectile Dysfunction Drugs
- Gender Dysphoria Drugs
- Hypoactive Sexual Desire Disorder Drugs
- Premature Ejaculation Drugs
- Others
- Global Sexual Health Market, By Gender:
- Global Sexual Health Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Sexual Health Market, By Region:
- North America
- By Product Type:
- Erectile Dysfunction Drugs
- Gender Dysphoria Drugs
- Hypoactive Sexual Desire Disorder Drugs
- Premature Ejaculation Drugs
- Others
- By Gender:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Europe
- By Product Type:
- Erectile Dysfunction Drugs
- Gender Dysphoria Drugs
- Hypoactive Sexual Desire Disorder Drugs
- Premature Ejaculation Drugs
- Others
- By Gender:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- Erectile Dysfunction Drugs
- Gender Dysphoria Drugs
- Hypoactive Sexual Desire Disorder Drugs
- Premature Ejaculation Drugs
- Others
- By Gender:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- By Product Type:
- Erectile Dysfunction Drugs
- Gender Dysphoria Drugs
- Hypoactive Sexual Desire Disorder Drugs
- Premature Ejaculation Drugs
- Others
- By Gender:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- By Product Type:
- Erectile Dysfunction Drugs
- Gender Dysphoria Drugs
- Hypoactive Sexual Desire Disorder Drugs
- Premature Ejaculation Drugs
- Others
- By Gender:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- Erectile Dysfunction Drugs
- Gender Dysphoria Drugs
- Hypoactive Sexual Desire Disorder Drugs
- Premature Ejaculation Drugs
- Others
- By Gender:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Meda Pharmaceuticals, Inc.
- Eli Lilly & Company
- Bayer AG
- Vivus, Inc.
- Zydus Pharmaceuticals
- IVFTECH APS
- Merck & Co.
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Novartis International AG
- Mylan Pharmaceuticals Inc.
- AstraZeneca
“*” marked represents similar segmentation in other categories in the respective section.
